Bacitracin and Ceftazidime drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Bacitracin (bacitracin) and Ceftazidime (ceftazidime). Common drug interactions include atelectasis among females and tachycardia among males.

The phase IV clinical study analyzes what interactions people have when they take Bacitracin and Ceftazidime. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Bacitracin?

Bacitracin has active ingredients of bacitracin. eHealthMe is studying from 1,214 Bacitracin users. Check the latest studies of Bacitracin.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.



On Jul, 12, 2026

18 people who take Bacitracin and Ceftazidime together, and have interactions are studied.

Bacitracin and Ceftazidime drug interactions.

What are the common drug interactions of Bacitracin and Ceftazidime, by gender? *:

female:

  1. Atelectasis (partial or complete collapse of the lung)
  2. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  3. Blood glucose increased
  4. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  5. Cardiac failure congestive
  6. Cardiomegaly (increased size of heart than normal)
  7. Chest discomfort
  8. Cholecystitis (infection of gallbladder)
  9. Cough
  10. Enterobacter pneumonia (lung inflammation caused by bacteria of the family enterobacteriaceae)

male:

  1. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  2. Thrombocytopenia (decrease of platelets in blood)
  3. Alopecia (absence of hair from areas of the body)
  4. Aspergillosis (an infection caused by a fungus called aspergillus)
  5. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  6. Candidiasis (candidiasis or thrush is a fungal infection)
  7. Cyanosis (lack of oxygen in body leads to blue appearance of skin ,mucous membrane nails)
  8. Failure to thrive (inadequate weight gain and physical growth in children)
  9. Fluid overload (too much fluid in the blood)
  10. Gastroenteritis (inflammation of stomach and intestine)

What are the common drug interactions of Bacitracin and Ceftazidime, by age (0-1 to 60+)? *:

0-1:

  1. Pyrexia (fever)
  2. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  3. Thrombocytopenia (decrease of platelets in blood)
  4. Abdominal distension
  5. Alopecia (absence of hair from areas of the body)
  6. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  7. Candidiasis (candidiasis or thrush is a fungal infection)
  8. Cyanosis (lack of oxygen in body leads to blue appearance of skin ,mucous membrane nails)
  9. Failure to thrive (inadequate weight gain and physical growth in children)
  10. Fluid overload (too much fluid in the blood)

2-9:

  1. Pancreatitis (inflammation of pancreas)
  2. Sepsis (a severe blood infection that can lead to organ failure and death)
  3. Caecitis (inflammation of the cecum)

10-19:

  1. Asthenia (weakness)
  2. Cardiomyopathy (weakening of the heart muscle)
  3. Dyspnoea (difficult or laboured respiration)
  4. Enterobacter pneumonia (lung inflammation caused by bacteria of the family enterobacteriaceae)
  5. Epistaxis (bleed from the nose)
  6. Heart rate decreased
  7. Hyperglycaemia (high blood sugar)
  8. Hypertension (high blood pressure)
  9. Hypotension (abnormally low blood pressure)
  10. Ileus (a painful obstruction of the ileum or other part of the intestine)

20-29:

  1. Abdominal pain upper
  2. Asthenia (weakness)
  3. Atelectasis (partial or complete collapse of the lung)
  4. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  5. Blood glucose increased
  6. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  7. Cardiac failure congestive
  8. Cardiomegaly (increased size of heart than normal)
  9. Cardiomyopathy (weakening of the heart muscle)
  10. Chest discomfort

30-39:

n/a

40-49:

n/a

50-59:

  1. Cardiomegaly (increased size of heart than normal)
  2. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  3. Pulmonary oedema (fluid accumulation in the lungs)

60+:

  1. Aspergillosis (an infection caused by a fungus called aspergillus)
  2. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  3. Enterococcal infection
  4. Hypotension (abnormally low blood pressure)
  5. Ileus paralytic (obstruction of the intestine due to paralysis of the intestinal muscles)
  6. Immunosuppression
  7. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  8. Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  9. Multi-organ failure (multisystem organ failure)
  10. Nephropathy (damage to or disease of a kidney)

What are the existing conditions these people have? *

  1. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 3 people, 16.67%
  2. High Blood Pressure: 3 people, 16.67%
  3. Neurotrophic Keratopathy (decreased corneal sensitivity and poor corneal healing): 2 people, 11.11%
  4. Haemostasis (stopping of bleeding): 2 people, 11.11%
  5. Wound Infection: 2 people, 11.11%
  6. Medical Device Complication: 2 people, 11.11%
  7. Peripartum Cardiomyopathy (deterioration in cardiac function presenting typically between the last month of pregnancy and up to five months postpartum): 1 person, 5.56%
  8. Pain: 1 person, 5.56%
  9. Rashes (redness): 1 person, 5.56%
  10. Nausea (feeling of having an urge to vomit): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Bacitracin and Ceftazidime?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Bacitracin and Ceftazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Bacitracin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ceftazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Bacitracin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ceftazidime and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on bacitracin and ceftazidime (the active ingredients of Bacitracin and Ceftazidime, respectively), and Bacitracin and Ceftazidime (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: